Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5153MR)

This product GTTS-WQ5153MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5153MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2816MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ9401MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ8559MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ5703MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ1406MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ9193MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ13508MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ10069MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW